Caxton Associates
2
40M
2
0.05
2
- Areas of investment
Summary
Caxton Associates appeared to be the VC, which was created in 1983. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the New York.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The increased amount of exits for fund were in 2018. The top activity for fund was in 2010. The fund is generally included in less than 2 deals every year.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Health Care, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Anthera Pharmaceuticals, Synta Pharmaceuticals.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Caxton Associates, startups are often financed by VantagePoint Capital Partners, Sofinnova Investments, Pappas Ventures. The meaningful sponsors for the fund in investment in the same round are SunAmerica, OrbiMed, Mountain Trail Investments.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Exits
- 2
- Rounds per year
- 0.05
- Investments by industry
- Biotechnology (2)
- Pharmaceutical (2)
- Health Care (2)
- Medical (1)
- Investments by region
-
- United States (2)
- Peak activity year
- 2010
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Synta Pharmaceuticals | 14 Jan 2004 | Biotechnology, Health Care, Medical, Pharmaceutical | Late Stage Venture | 50M | United States, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.